National Pharmacy Health & Leadership Alliance Verify a MemberMember Login

What changed today in Metabolic: 4 trial updates

Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.

The signal

NPHLA tracked 4 new official records on this desk today: 4 trial updates.

Why this matters

GLP-1 and obesity-medicine developments can change access, supply, clinical evidence and patient conversations for clinics, pharmacies and prescribers.

What changed

  1. New trial registered: Effects of a Gut-Active Peptide That Stimulates GLP-1 Release on Appetite and Satiety in Healthy Adults With Overweight[1]
  2. New trial registered: A Phase I Study to Evaluate the Food Effect on Ecnoglutide Tablet[2]
  3. Trial status changed to “Completed”: A Study of BGM0504 in Participants With Type 2 Diabetes[3]
  4. New trial registered: Safety and Pharmacokinetics of UI112 Compared With UIC202611 in Healthy Adults[4]

Who this affects

  • Weight-management clinics
  • Med spas
  • Pharmacists
  • Prescribers
  • Medical directors
  • Practice owners & operators

What to watch next

No new verified deadlines in today’s records. See Deadline Watch for upcoming dates.

NPHLA takeaway

These are factual summaries of official records with no interpretation. Open the primary documents for full details; NPHLA editors add analysis where developments warrant it.

Source file

  1. [1]
  2. [2]
    New trial registered: A Phase I Study to Evaluate the Food Effect on Ecnoglutide Tablet (opens the source in a new tab)

    Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)

  3. [3]
  4. [4]

Compiled automatically from primary official sources and peer-reviewed literature. Each line is a factual summary of a public record, linked to it — no interpretation is added. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.